Imidocarb

1,3-bis [ 3 - (2 - imidazolin-2- yl) phenyl] urea

• 27885-92-3 ( Imidocarb )
• 5318-76-3 ( Imidocarb · dihydrochloride)

QP51AE01

Antiprotozoic

Inhibitors of nucleic acid synthesis

• 348.40 g · mol -1 ( Imidocarb )
• 421.32 g · mol -1 ( Imidocarb · dihydrochloride)

350 ° C ( decomposition) ( Imidocarb · dihydrochloride)

Template: Infobox chemical / molecular formula search available

Imidocarb is a term used in veterinary medicine drug from the group of Carbanilides, which is primarily used for the treatment and prevention of Babesiosis. It is used mainly as Imidocarbdipropionat ( CAS number 27885-92-3 ) application. In human medicine, the drug is not approved.

Mechanism of action and applications

The exact mechanism of action is not yet finally resolved. Imidocarb binds to the DNA of Babesia and so suppresses the nucleic acid synthesis. It also inhibits the synthesis of polyamines probably. The drug is metabolized and excreted slowly in vertebrates. The half-life in blood is about 3 hours. Excretion is about 90% through the kidneys and the remainder in the faeces.

Except Babesia, the active ingredient for the treatment of Cytauxzoonose, eperythrozoonosis, Hepatozoonose, theileriosis and canine ehrlichiosis is suitable. In lactating animals, the drug should not be used.

Side effects

At the injection site may result in a painful swelling.

The systemic side effects are mainly due to an inhibition of cholinesterase and consist of nausea, vomiting, salivation, tremors, lacrimation, defecation and urination, colic, serous nasal discharge. Rarely, diarrhea and shortness of breath. These symptoms can be alleviated by administration of atropine.

Rarely enters an anaphylactic reaction.

Trade names

Carbesia ®, Imizol ®